PATENT CLAIM ANALYSIS

Application Number: 16068272
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "255050"]

Abstract:
Provided herein are compounds of the formula I: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.

Claim (Index 19):
The use of a compound according to  claim 17  for the treatment of Alzheimer's disease, Parkinson's disease, levodopa-induced dyskinesia in Parkinson's disease (PD-LID), Huntington's chorea, psychiatric disorders, schizophrenia, mood disorders, emotion disorders, attention deficit disorders, Fragile X syndrome, autism spectrum disorders (ASDs), gastroesophageal reflux disease (GERD), drug addiction, depression disorders.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 95.0
- Lexical Diversity: 1.56522
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16091781', '15771920', '11360085', '11726807', '14344957']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8274758011809494
- 35 USC 102 Novelty (BERT): 0.548296459061081
- Combined Prediction Score: 0.7995578669689626
- Mean Citation Score: 373.213428
- Max Citation Score: 444.10822
- Similarity Product: 260.81075563672783

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test